Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
Condition: Healthy
Study type: Interventional
Phase: Phase 2

Summary: 
      This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study.
      The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the
      anti-platelet effects of ticagrelor as part of a dual antiplatelet regimen and to evaluate
      the safety and tolerability of bentracimab (PB2452) in subjects aged 50-80 years old.

      A total of 205 subjects between 50-80 years old will be enrolled in the US or other countries
      at the discretion of the Sponsor across 5-15 sites. The subjects will be randomized at a
      ratio of 3:1 receiving either the bentracimab (PB2452) investigational study drug or placebo.
      Hence, a total of 154 subjects will be receiving bentracimab (PB2452) and approximately 51
      subjects will be receiving placebo.
    

Detailed description: 
      The study will consist of a Screening period, a Check-in day, an on-site
      Randomization/Treatment day, a 2-day on-site Follow-up period (Days 2 through 3), a Follow-up
      visit (Day 7), and a Final Follow-up visit (Day 35±3). If needed and at the discretion of the
      Investigator, a subject may remain in the study facility beyond the scheduled Day 3 discharge
      to accommodate Day 7 and Day 35±3 follow-up visits. Seven days prior to enrollment, subjects
      will be administered ASA 81 mg orally once daily (QD) until the final dose on Day 1.
      Beginning in the morning on Day -2, a single dose of oral ticagrelor 180 mg will be given,
      followed by oral ticagrelor 90 mg every 12 hours for 4 additional doses through to Day 1 (2
      hours before study drug is initiated; this will be 5 total doses of ticagrelor).

      On Day 1, subjects who meet all the inclusion criteria and none of the exclusion criteria
      will be randomized with 3:1 allocation ratio (active:placebo), to receive an IV dose of
      bentracimab (PB2452) or placebo 2 hours following the 5th ticagrelor dose. Subjects may be
      discharged from the clinical site on Day 3 and will return for a Follow-up visit on Day 7, if
      already discharged, and on Day 35 (±3 days). A subject may remain in the study facility
      beyond the scheduled Day 3 discharge to accommodate Day 7 and Day 35±3 follow-up visits.

      If a subject is taking a moderate or strong CYP3A inhibitor, a 36 g alternative regimen of
      bentracimab (PB2452) will be administered consisting of 12 g infused over 10 minutes followed
      by a 12 g loading dose infused over 6 hours, then a maintenance dose of 12 g infused over the
      next 18 hours immediately following completion of the loading period for a total infusion
      time of approximately 24 hours.
    

Intervention name(s): Ticagrelor Oral Tablet - Pre-Treatment; Aspirin (ASA) Oral Tablet - Pre-Treatment; Bentracimab (PB2452) Infusion; Placebo (0.9% Sodium chloride) infusion
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.; Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.; Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration
In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion.; 0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
Intervention MeSH terms: Aspirin; Ticagrelor
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment